检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:丛翠翠[1] 朱芸[2] 李明[2] 马晶晶[2] 赵雪丽[2]
机构地区:[1]潍坊医学院内科学教研室,山东潍坊261053 [2]潍坊医学院附属潍坊市人民医院风湿免疫科
出 处:《潍坊医学院学报》2011年第2期93-95,共3页Acta Academiae Medicinae Weifang
摘 要:目的 检测血清软骨寡聚基质蛋白(COMP)水平在糖皮质激素治疗类风湿关节炎(RA)的前后变化以评价糖皮质激素在抑制RA软骨破坏中的意义.方法 收集急性活动期RA患者59例(未接受过糖皮质激素治疗,无内脏受累),随机分为激素治疗组和非激素治疗组,两组均以慢作用抗风湿药物为基础用药,分别予治疗前、治疗后1周、2周及4周时记录COMP、血沉(ESR)、C反应蛋白(CRP)等指标,评估DAS28评分、ACR70等并进行比较.另取18例正常对照组,检测血清COMP水平.结果 RA患者COMP水平较正常对照组高,激素治疗组COMP水平下降较未用激素组明显,差异具有统计学意义.结论 COMP可作为关节软骨破坏的生物学标记物,并可用于RA的疗效评估.联合应用小剂量激素可迅速、明显地缓解RA的关节症状,降低血清COMP水平,推断其可缓解软骨破坏进展.Objective To detect the serum level of cartilage oligomeric matrix protein(COMP) in patients with rheumatoid arthritis(RA) undergoing steroid treatment in order to evaluate the significance of steroid treatment in RA. Methods Fifty-nine adult patients with active RA were randomly divided into the study group and the control group. Both the two groups were treated with disease-modifying antirheumatic drugs( DMARDs). Eighteen healthy people were chosen as the control group and serum level of COMP was measured. Simultaneously,the levels of erythrocyte sedimentation rate( ESR), C-reactive protein( CRP), DAS28 and ACR70 were measured in RA group 0,1,2 and 4 weeks atter the treatment. Finally,the above mentioned parameters were analysed. Results Compared with the control group,the serum level of COMP elevated in the RA group,and the serum COMP level of patients undergoing steroid treatment decreased significantly within 4 weeks. Conclusion COMP seems not only to be as a valuable parameter of cartilage deg-radation,but also as a marker for monitoring the therapy response in patients with RA. The treatment with steroids in pa-tients with highly active RA leads to a significant decrease of COMP level and has a rapid chondro-protective effect.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:3.148.236.97